Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285070 · ClinicalTrials.gov registry record · Phase 2
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
A Phase 2 study, sponsored by Novaliq.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07285070 is a Phase 2 study that is actively recruiting participants, run by Novaliq. The registered enrollment target is 20 participants.
The verdict
NCT07285070, a Phase 2 study, is actively recruiting participants, sponsored by Novaliq.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
Interventions
- DRUG Tacrolimus ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07285070
The ClinicalTrials.gov registry entry for NCT07285070 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novaliq, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus ophthalmic solution is the first listed.
NCT07285070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07285070 about?
NCT07285070 is a clinical study titled "Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis". The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
What is the current status of trial NCT07285070?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-03-16. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07285070?
The interventions under investigation include: Tacrolimus ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT07285070?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.